Nanologica will be attending BIO-Europe in Paris, Mar. 23-25, to meet with potential pharmaceutical partners regarding co-development and licensing of NIC-001, Nanologica’s drug candidate for treating gastroparesis, as well as seeking partnership for further drug delivery applications using NLAB Silica™ and NLAB Spiro™.
Nanologica’s drug delivery platforms NLAB Silica™ and NLAB Spiro™ consists of nanoporous particles where APIs can be placed inside the pores. By loading the API into the particles, Nanologica can overcome several of the challenges that prevent or limit effective treatment of many serious diseases. Some of the benefits of using Nanologica’s drug delivery platforms include improving solubility, enhancing bioavailability and protecting APIs from degradation.
“We are excited to once again attend BIO-Europe as our previous visits have been very fruitful and have brought about exciting leads regarding the use of our drug delivery platforms”, says Kia Bengtsson, Director Drug Development Nanologica.
Nanologica is interested in partnering with pharma companies within the gastrointestinal area regarding the Company’s own asset NIC-001 and is also seeking partnership for further drug delivery applications using the company’s drug delivery platforms NLAB Silica™ and NLAB Spiro™.
“When we presented our inhalation platform NLAB Spiro™ at BIO-Europe in Hamburg, we received a great interest. We now look forward to further demonstrate and discuss the possibilities the platform has when it comes to inhaled APIs”, says prof. Adam Feiler, CTO Nanologica.
Nanologica is currently involved in several clinical trials, with its own asset NIC-001 which is a drug candidate in phase II for the treatment of gastroparesis, as well as in collaboration projects with large and mid-size pharma.
NIC-001 is a reformulation of metoclopramide for sublingual administration. Metoclopramide is a substance used to treat nausea and vomiting, and is the only drug approved by the FDA for the treatment of gastroparesis. The efficacy of existing metoclopramide-based drugs varies however widely, and the drugs are ineffective for many patients. The purpose of NIC-001 is to address these issues by bypassing the impaired gastrointestinal tract. The expected advantage of NIC-001 is a faster and more consistent symptom relief, and increased comfort for patients. The medical need is large as the treatment options for affected patients are few.
For inhalation, Nanologica produces spherical particles in the size range of 2 μm to 5 μm with narrow particle size distribution to reach the desired target site in the lung. The particles are non-aggregating, soluble in simulated lung fluid, carry a high drug load and offer a controlled and sustained release profile. Nanologica is currently involved in a partner project progressing towards a phase I study, based on the platform NLAB Spiro™.
To schedule a meeting, please do so via BIO-Europe’s online partnering platform at: www.partneringone.com, or contact:
Kia Bengtsson, Director Drug Development Nanologica
Ph: +46 70 144 36 30 or e-mail: firstname.lastname@example.org
For technical information on Nanologica’s drug delivery platform, please contact:
Prof. Adam Feiler, CTO Nanologica
Ph: +46 72 353 66 30 or e-mail email@example.com
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.